Dr. Shanta Dhar (IMAGE) University of Miami Miller School of Medicine Caption “We made a dual-targeted nanoparticle,” said Dr. Shanta Dhar, assistant director of Technology and Innovation at Sylvester Comprehensive Cancer Center. “The first targeting is needed to get it through the gut barrier, and the second targeting takes it to the prostate. The beauty is, now we can deliver a chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy.” Credit Photo by Sylvester Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.